Clinical Observation Of Jiawei Liujunzi Decoction In The Treatment Of COPD Stablility Of Lung-spleen Qi Deficiency And Blood Stasis Syndrome And Its Effect On Serum CC16

Objective:To observe the effects of Jiawei Liujunzi Decoction on TCM clinical symptom score,Lung function,CAT score and serum CC16 in the stable stage of chronic obstructive pulmonary disease(Lung-Spleen Qi Deficiency and Blood Stasis Syndrome),and evaluate its clinical efficacy and safety.Methods:From May 2019 to December 2019,76 patients who attended the outpatient department of Respiratory Clinic of the First Affiliated Hospital of Heilongjiang University of Chinese Medicine and met the inclusion criteria for the stable period of COPD(Lung-Spleen Qi Deficiency and Blood Stasis Syndrome)were randomly divided into treatment groups and in the control group,there were 38 cases in the treatment group(2 case was lost to follow-up,and 1 case was not taken as prescribed).The actual number of completed trials was 35;in the control group,38 cases(1 patients withdrew from the test due to acute exacerbation of the disease,1 case was lost to follow-up),36 cases were actually completed.The treatment group received Jiawei Liujunzi Decoction,one dose daily,300 ml of water decoction,150 ml divided in morning and evening.The control group received salmeterol and fluticasone powder inhalation,1 inhalation each time,2 times a day.Both groups were treated for 8 weeks.To observe the changes of TCM clinical symptom score,Lung function,CAT score and the effect on serum CC16 before and after treatment in the two groups of patients.Results:1.The total effective rate of the treatment group was 94.29 %,and the total effective rate of the control group was 83.33%.The clinical efficacy of the treatment group was better than that of the control group(P<0.05).2.The clinical symptom scores of TCM after treatment in both groups were improved compared with before treatment(P<0.05),and the treatment group was better than the control group(P<0.05).3.The lung function of the two groups after treatment was improvedcompared with that before treatment(P<0.05),and there was no statistical significance between the two groups after treatment(P>0.05).4.The CAT scores of the two groups were improved after treatment(P<0.05),and the CAT score of the treatment group was lower than that of the control group(P<0.05).5.The level of serum CC16 increased after treatment in the two groups,which was statistically significant before and after treatment(P <0.05).After treatment,the treatment group was superior to the control group(P <0.05).6.There were no significant abnormal changes in safety indicators before and after treatment.Conclusion:1.Jiawei Liujunzi Decoction can reduce the score of TCM clinical symptoms in patients with chronic obstructive pulmonary disease in the remission period(Lung-Spleen Qi Deficiency and Blood Stasis Syndrome).2.Jiawei Liujunzi Decoction can improve the lung function of patients with chronic obstructive pulmonary disease in stable stage(Lung-Spleen Qi Deficiency and Blood Stasis Syndrome).3.Jiawei Liujunzi Decoction can reduce the CAT score of patients with chronic obstructive pulmonary disease in the remission period(Lung-Spleen Qi Deficiency and Blood Stasis Syndrome).4.Jiawei Liujunzi Decoction can increase the serum CC16 level in patients with chronic obstructive pulmonary disease in the remission period(Lung-Spleen Qi Deficiency and Blood Stasis Syndrome).5.Jiawei Liujunzi Decoction is safe and effective in the treatment of chronic obstructive pulmonary disease in the remission period(Lung-Spleen Qi Deficiency and Blood Stasis Syndrome).